Glucagon-like Peptide-1 Receptor Agonists in Mental Health – Cognitive and Psychiatric Outcomes

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have become important medications in health care. They are mainly recognized for treating diabetes and aiding weight management. Large research indicate that GLP-RAs do not significantly increase the risk of psychiatric issues and show benefits for both physical and mental well-being, including improvements in quality of life, emotional eating, and appetite control. GLP-1-RA affects the brain by interacting with various pathways that influence hunger and reward response. They can enhance brain energy balance, reduce inflammation, and support areas of the brain responsible for mood and cognition. Observations show that these medications can decrease brain activity in regions linked to appetite when patients view food, thus helping to reduce food intake. Some studies suggest that GLP-1-RAs may lower depression and anxiety risks, especially with certain medications like tirzepatide. However, other research indicates an increased risk of psychiatric issues among some users, particularly women and younger patients. Users report a mix of experiences, with many experiencing mood improvements, while others encounter new or worsening depressive symptoms. Social media analysis supports varied patient responses, outlining experiences of both mental health improvements and declines after using GLP-1-RAs. Pharmacovigilance data indicate a notable number of adverse psychiatric events reported, prompting a cautious approach from healthcare providers. Overall, GLP-1-RAs showcase a complex relationship with mental health, highlighting their potential benefits and risks. Clinicians should remain vigilant, especially with patients who have preexisting psychiatric conditions, while considering collaboration with mental health professionals to optimize treatment outcomes.